新活素联合左西孟旦治疗慢性心衰急性发作的临床效果观察  

Observation on the clinical effect of Xinhuosu combined with levosimendan in the treatment of acute attack of chronic heart failure

作　　者：朱美润 郎爽[1] 邢卓 吴天兵[1] ZHU Mei-run;LANG Shuang;XING Zhuo(Shenyang Red Cross Hospital,Shenyang 110013,China)

机构地区：[1]沈阳市红十字会医院,110013

出　　处：《中国现代药物应用》2022年第1期17-19,共3页Chinese Journal of Modern Drug Application

摘　　要：目的分析冻干重组人脑利钠肽(商品名:新活素)联合左西孟旦治疗慢性心力衰竭(心衰急性发作的临床效果。方法 86例慢性心衰急性发作患者,按照奇偶法分为对照组和观察组,每组43例。对照组患者采用左西孟旦治疗,观察组患者采用新活素联合左西孟旦治疗。比较两组患者治疗效果及治疗前后心功能指标[左心室射血分数(LVEF)、左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)]、尿量及血尿素氮(BUN)水平。结果观察组患者治疗总有效率为95.35%,高于对照组的76.74%,差异具有统计学意义(P<0.05)。治疗后,观察组患者LVEF(49.94±5.69)%高于对照组的(42.92±5.29)%, LVESV(92.36±8.45)ml、LVEDV(128.36±11.55)ml小于对照组的(97.54±7.12)、(137.51±13.19)ml,差异具有统计学意义(P<0.05)。治疗后,观察组患者尿量(1202.15±247.34)ml/d多于对照组的(994.72±289.39)ml/d, BUN水平(6.91±1.25)mmol/L低于对照组的(8.22±2.04)mmol/L,差异具有统计学意义(P<0.05)。结论新活素联合左西孟旦治疗慢性心衰急性发作可以改善患者心功能,增加排尿量,具有较高的临床应用价值。Objective To analyze the clinical effect of lyophilized recombinant human brain natriuretic peptide(trade name: Xinhuosu) combined with levosimendan in the treatment of acute attack of chronic heart failure. Methods A total of 86 patients with acute attack of chronic heart failure were divided into control group and observation group according to the odd-even method, with 43 cases in each group. Patients in the control group were treated with levosimendan, and patients in the observation group were treated with Xinhuosu and levosimendan. Both groups were compared in terms of therapeutic effect and cardiac function indexes [left ventricular ejection fraction(LVEF), left ventricular end diastolic volume(LVEDV), left ventricular end systolic volume(LVESV)], urine output and blood urea nitrogen(BUN) before and after treatment. Results The total effective rate of treatment in the observation group was 95.35%, which was higher than 76.74% in the control group, and the difference was statistically significant(P<0.05). After treatment, the LVEF(49.94±5.69)% of the observation group was higher than(42.92±5.29)% of the control group, and the LVESV(92.36±8.45) ml and LVEDV(128.36±11.55) ml were smaller than(97.54±7.12) and(137.51±13.19) ml of the control group. All the differences were statistically significant(P<0.05). After treatment, the urine output(1202.15±247.34) ml/d of the observation group was more than(994.72±289.39) ml/d of the control group, and the BUN level(6.91±1.25) mmol/L was lower than(8.22±2.04) mmol/L of the control group. All the differences were statistically significant(P<0.05). Conclusion Xinhuosu combined with levosimantane in the treatment of acute attack of chronic heart failure can optimize patients’ heart function and increase urine output, which has high value of clinical application.

关 键 词：冻干重组人脑利钠肽 左西孟旦 慢性心力衰竭 急性发作 

分 类 号：R541.6[医药卫生—心血管疾病]